Држава: Велика Британија
Језик: Енглески
Извор: VMD (Veterinary Medicines Directorate)
Clindamycin
Chanelle Animal Health Ltd
QJ01FF01
Clindamycin
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Antimicrobial
Authorized
2010-02-10
Revised: September 2020 AN. 00334/2020 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Clinacin 300 mg Tablets for Dogs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Clindamycin (as Clindamycin Hydrochloride) 300 mg EXCIPIENTS: For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Tablet A plain white to off white tablet with a cross breakline on one side. The tablets can be divided into halves or quarters. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Clinacin 300 mg Tablets are indicated for the treatment of infected wounds, abscesses, superficial pyoderma and oral cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae, _Fusobacterium necrophorum_, _ Clostridium perfringens_ and osteomyelitis caused by _Staphylococcus aureus_. Clinacin 300 mg Tablets can also be used to help provide antimicrobial cover during dental procedures. 4.3 CONTRAINDICATIONS Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations. Do not administer to rabbits, guinea pigs, chinchillas, hamsters, horses or ruminants. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Before the use of Clinacin 300 mg tablets, the identification of causative pathogenic micro-organisms should be carried out and the sensitivity to clindamycin should be established. Clindamycin and lincomycin show parallel resistance. There is a partial cross-resistance to erythromycin and other macrolide antibiotics. Revised: September 2020 AN. 00334/2020 Page 2 of 5 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored Прочитајте комплетан документ